FIELD: medicine.
SUBSTANCE: claimed invention relates to biotechnology. Claimed is a monoclonal antibody, which specifically binds with the second Kunitz domain of a tissue factor pathway inhibitor (TFPI), which is characterised by the fact that it contains 6CDR. Described are: cell, expressing the said antibody, and the application of the antibody for the treatment of a subject with coagulopathy.
EFFECT: application of the invention makes it possible to provide novel antibodies, which can be applied in therapy for the reduction of the blood coagulation time.
6 cl, 24 dwg, 12 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AGAINST TISSUE FACTOR PATHWAY INHIBITOR AND USE THEREOF | 2016 |
|
RU2705540C2 |
| ANTIBODIES AGAINST TISSUE FACTOR PATHWAY INHIBITOR AND THEIR USE | 2016 |
|
RU2815681C1 |
| ANTI-IGF-1R ANTIBODY AND USE THEREOF AS AN ADDRESS VECTOR FOR CANCER TREATMENT | 2015 |
|
RU2698977C2 |
| HUMANISED ANTIBODIES TO Toll-LIKE RECEPTORS 2 AND THEIR APPLICATIONS | 2010 |
|
RU2563344C2 |
| ANTIBODIES AGAINST HUMAN IL33R AND USE THEREOF | 2012 |
|
RU2597288C2 |
| ANTI-CXCR4 ANTIBODIES AND USING THEM FOR TREATING CANCER | 2009 |
|
RU2573897C2 |
| ANTI-cMet ANTIBODY AND USE THEREOF FOR DETECTION AND DIAGNOSIS OF CANCER | 2010 |
|
RU2582265C2 |
| SPECIFIC LINKING AGENTS AGAINST B7-H1 | 2010 |
|
RU2571204C2 |
| SPECIFIC BINDING AGENTS AGAINST B7-H1 | 2010 |
|
RU2706200C2 |
| ANTIBODIES SPECIFIC FOR LIGAND 1A, SIMILAR TO TUMOR NECROSIS FACTOR, AND THEIR COMPOSITIONS AND APPLICATION | 2014 |
|
RU2708140C1 |
